mechanism of action for glp 1 receptor agonists Current Insights, Advantages and Challenges Small Molecule Glucagon-like Peptide Agonists: A Scoping Review Mechanisms of GLP-1 Receptor Agonist-Induced

In some of the studies, an additional 10% dose reduction was done with drug escalation

Saxena AR, Frias JP, Brown LS, Gorman DN, Vasas S, Tsamandouras N, et al

Retatrutide shows mostly hepatic metabolism but does not interact with cytochrome P450 enzymes [36]

It is important to note that while GLP-1RAs have demonstrated CV safety, not all result in an actual reduction in CV adverse events, such as exenatide QW and lixisenatide, both of which were reported to be non-inferior to placebo for MACE [22, 23]

For Canadians comparing research peptide options, this efficacy difference represents the primary advantage of the triple-agonist mechanism